Amgen announced positive Phase 3 results from the MINT trial, showing UPLIZNA significantly improves symptoms in patients with generalized myasthenia gravis (gMG) who are acetylcholine receptor autoantibody-positive (AChR+). Over 52 weeks, patients receiving UPLIZNA experienced sustained symptom relief with just two doses per year. The findings will be presented at the American Academy of Neurology (AAN) Annual Meeting on April 8, 2025.

UPLIZNA showed a greater reduction in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores compared to placebo. Among AChR+ patients, 72.3% had a ≥3 point improvement in MG-ADL scores versus 45.2% in the placebo group. Safety findings were consistent with its known profile.

UPLIZNA is currently approved for neuromyelitis optica spectrum disorder (NMOSD) and is under FDA review for Immunoglobulin G4-related disease (IgG4-RD). Regulatory filings for gMG treatment are expected to be completed in the first half of 2025.

For more information, visit Amgen.com.